首页> 外文OA文献 >Histopathological Features of Methotrexate Induced Pulmonary Lesions in Rheumatoid Arthritis Patients: A Systematic Review of Case Reports
【2h】

Histopathological Features of Methotrexate Induced Pulmonary Lesions in Rheumatoid Arthritis Patients: A Systematic Review of Case Reports

机译:类风湿关节炎患者甲氨蝶呤诱发的肺部病变的组织病理学特征:病例报告的系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Methotrexate (MTX) is the most commonly used disease-modifying drug in the treatment of rheumatoid arthritis (RA); however, it causes many side effects, including pulmonary lesions. In this review, we characterised the histopathological features of MTX-induced pulmonary lesions in RA patients.AIM: We carried out an electronic search of the relevant literature published during the period from 1990 to 2016. We included only the cases with definitive histo-pathological findings caused by MTX therapy.MATERIAL AND METHODS: The total number of cases is 27. Male: female ratio was 1:3, and ages ranged from 48 to 87 years old, with a mean (SD) = 65.7 (1.0). The cases were originally from Asia (55%), Europe (41%), and America (4%). The major complications of methotrexate therapy were lymphoproliferative disorders (42%) followed by interstitial fibrosis (33), and infections (25%). The incidence of these complications significantly increases with the duration of MTX treatment (p = 0.044). Among the infections, the most common causative organism was pneumocystis jiroveci. The majority of patients who developed infections following methotrexate therapy were from Europe whereas the majority of those who developed lymphoproliferative disorders were from Asia (p = 0.003).CONCLUSION: In conclusion, methotrexate therapy in rheumatoid arthritis patients causes different types pulmonary complications.
机译:背景:甲氨蝶呤(MTX)是类风湿关节炎(RA)治疗中最常用的疾病缓解药物。但是,它会引起许多副作用,包括肺部病变。在这篇综述中,我们表征了MTX诱发的RA患者肺部病变的组织病理学特征。目的:我们对1990年至2016年期间发表的相关文献进行了电子检索。我们仅包括了明确的组织病理学病例材料与方法:病例总数为27。男性与女性的比例为1:3,年龄范围为48至87岁,平均(SD)= 65.7(1.0)。这些病例最初来自亚洲(55%),欧洲(41%)和美国(4%)。氨甲蝶呤治疗的主要并发症是淋巴增生性疾病(42%),其后是间质纤维化(33)和感染(25%)。这些并发症的发生率随着MTX治疗持续时间的增加而显着增加(p = 0.044)。在感染中,最常见的致病菌是次生肺孢子菌。结论:甲氨蝶呤治疗类风湿关节炎患者会引起不同类型的肺部并发症,其中大多数患者在欧洲接受甲氨蝶呤治疗后感染,而大多数淋巴增生性疾病患者来自亚洲(p = 0.003)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号